JABFM
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Rapid Responses: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Rapid Responses are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lipsky, M. S.
Right arrow Articles by Sharp, L. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lipsky, M. S.
Right arrow Articles by Sharp, L. K.

The Journal of the American Board of Family Practice, Vol 13, Issue 3 178-182, Copyright © 2000 by American Board of Family Practice


ARTICLES

Impact of vaginal antifungal products on utilization of health care services: evidence from physician visits

M. S. Lipsky, T. Waters and L. K. Sharp
Department of Family Medicine, Northwestern University Medical School, Chicago 60611, USA.

BACKGROUND: Recently many medications formerly available only by prescription have been approved for over-the-counter (OTC) status. In 1990, clotrimazole became the first available OTC drug to treat candidal vaginitis. Subsequently several other prescription antifungal medications have also been available in OTC products. One proposed benefit of these switches from prescription to OTC status is a reduction in the utilization of health care services. METHODS: Using National Ambulatory Medical Care Survey data, the average numbers of annual visits for vaginal complaints were estimated for 1985, 1990, and 1994. These years were chosen because they represented periods before, close to, and after the approval of the OTC antifungal preparations. The estimated visits for each year were compared using a chi-square analysis with a sample weight correction. RESULTS: There was a 15% decline in the number of vaginitis visits from 1990 to 1994 that potentially could be attributed to the availability of the OTC antifungal preparations. The decrease in physician visits results in approximately $45 million in direct cost savings and another $18.75 million in indirect savings by reducing time lost from work. CONCLUSIONS: It appears that the availability of OTC anticandidal fungal preparations reduces the number of physician visits for vaginitis, resulting in cost savings.


This article has been cited by other articles:


Home page
J Am Board Fam MedHome page
D. G. Ferris, S. L. Francis, E. D. Dickman, K. Miler-Miles, J. L. Waller, and N. McClendon
Variability of Vaginal pH Determination by Patients and Clinicians.
J Am Board Fam Med, July 1, 2006; 19(4): 368 - 373.
[Abstract] [Full Text] [PDF]


Home page
Obstet GynecolHome page
D. G. Ferris, P. Nyirjesy, J. D. Sobel, D. Soper, A. Pavletic, and M. S. Litaker
Over-the-Counter Antifungal Drug Misuse Associated With Patient-Diagnosed Vulvovaginal Candidiasis
Obstet. Gynecol., March 1, 2002; 99(3): 419 - 425.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Board of Family Medicine.